Literature DB >> 24296355

Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes.

Mai Uesugi1, Atsuko Ojima2, Tomohiko Taniguchi2, Norimasa Miyamoto3, Kohei Sawada3.   

Abstract

INTRODUCTION: Cardiac hypertrophy is a leading cause of many cardiovascular diseases, including heart failure, but its pathological mechanism is not fully understood. This study used highly purified human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes to produce an in vitro hypertrophy model and characterize its gene expression and electrophysiological properties.
METHODS: For 7 days we cultured hiPSC-derived cardiomyocytes plated at high (2800-4800 cells/mm(2)) or low (500-1200 cells/mm(2)) cell density and assessed their cell size with confocal and fluorescence microscopy, their electrophysiological and pharmacological responses with multi-electrode array systems, and their gene expression patterns by using DNA microarray technology and quantitative PCR. We used quantitative PCR and Western blotting to compare the expression of potassium-channel genes between the hiPSC-derived cardiomyocytes and human fetal and adult hearts.
RESULTS: The hiPSC-derived cardiomyocytes showed spontaneous beating and similar pattern of α-actinin molecules regardless of plating density. However, cells plated at low density had the following characteristics compared with those at high density: 1) significant enlargement in size; 2) significant increase or decrease in expression of the cardiac hypertrophy-characteristic genes NPPA, ATP2A2, ANKRD1 and MYL2 in accordance with the progression of hypertrophy; 3) significant reduction in responses to the inhibitors of cardiac slow delayed-rectifier K(+) current (IKs), chromanol 293B and HMR1556, in a cell-density-dependent manner; and 4) significant reduction in the expression of the KCNQ1 and KCNJ2 genes coding the K(+) ion channels conducting each IKs and cardiac inward rectifier outward K(+) current (IK1). DISCUSSION: The enlargement, hypertrophy-characteristic and potassium ion channels gene expression of hiPSC-derived cardiomyocytes suggest that low-density plating was sufficient to induce cardiac hypertrophy. This model may be useful in elucidating mechanisms underlying the onset and progress of cardiac hypertrophy, because these cells can be cultured for several weeks.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac hypertrophy; Cardiomyocytes; Electrical remodeling; Human iPS; I(Ks) current; KCNQ1; Methods

Mesh:

Year:  2013        PMID: 24296355     DOI: 10.1016/j.vascn.2013.11.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  10 in total

1.  Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca2+-dependent PKC activation.

Authors:  Xiaorong Xu Parks; Elsa Ronzier; Jin O-Uchi; Coeli M Lopes
Journal:  J Mol Cell Cardiol       Date:  2019-03-18       Impact factor: 5.000

2.  Pluripotent stem cells as a platform for cardiac arrhythmia drug screening.

Authors:  Jordan S Leyton-Mange; David J Milan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-09

3.  Single-Cell Transcriptomic Analysis of Cardiac Differentiation from Human PSCs Reveals HOPX-Dependent Cardiomyocyte Maturation.

Authors:  Clayton E Friedman; Quan Nguyen; Samuel W Lukowski; Abbigail Helfer; Han Sheng Chiu; Jason Miklas; Shiri Levy; Shengbao Suo; Jing-Dong Jackie Han; Pierre Osteil; Guangdun Peng; Naihe Jing; Greg J Baillie; Anne Senabouth; Angelika N Christ; Timothy J Bruxner; Charles E Murry; Emily S Wong; Jun Ding; Yuliang Wang; James Hudson; Hannele Ruohola-Baker; Ziv Bar-Joseph; Patrick P L Tam; Joseph E Powell; Nathan J Palpant
Journal:  Cell Stem Cell       Date:  2018-10-04       Impact factor: 24.633

4.  A new system for profiling drug-induced calcium signal perturbation in human embryonic stem cell-derived cardiomyocytes.

Authors:  Kimberley J Lewis; Nicole C Silvester; Steven Barberini-Jammaers; Sammy A Mason; Sarah A Marsh; Magdalena Lipka; Christopher H George
Journal:  J Biomol Screen       Date:  2014-11-03

5.  Culture in Glucose-Depleted Medium Supplemented with Fatty Acid and 3,3',5-Triiodo-l-Thyronine Facilitates Purification and Maturation of Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Bin Lin; Xianming Lin; Maxine Stachel; Elisha Wang; Yumei Luo; Joshua Lader; Xiaofang Sun; Mario Delmar; Lei Bu
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-09       Impact factor: 5.555

Review 6.  Novel screening techniques for ion channel targeting drugs.

Authors:  Alison Obergrussberger; Sonja Stölzle-Feix; Nadine Becker; Andrea Brüggemann; Niels Fertig; Clemens Möller
Journal:  Channels (Austin)       Date:  2015-11-10       Impact factor: 2.581

Review 7.  Concise Review: Criteria for Chamber-Specific Categorization of Human Cardiac Myocytes Derived from Pluripotent Stem Cells.

Authors:  Christopher Kane; Cesare M N Terracciano
Journal:  Stem Cells       Date:  2017-06-27       Impact factor: 6.277

Review 8.  hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us.

Authors:  Sophie Kussauer; Robert David; Heiko Lemcke
Journal:  Cells       Date:  2019-10-28       Impact factor: 6.600

9.  Syncytium cell growth increases Kir2.1 contribution in human iPSC-cardiomyocytes.

Authors:  Weizhen Li; Julie L Han; Emilia Entcheva
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-09-28       Impact factor: 4.733

10.  Single-Cell Transcriptomics of Engineered Cardiac Tissues From Patient-Specific Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveals Abnormal Developmental Trajectory and Intrinsic Contractile Defects in Hypoplastic Right Heart Syndrome.

Authors:  Yin-Yu Lam; Wendy Keung; Chun-Ho Chan; Lin Geng; Nicodemus Wong; David Brenière-Letuffe; Ronald A Li; Yiu-Fai Cheung
Journal:  J Am Heart Assoc       Date:  2020-10-16       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.